PepVault
/ database / GLP-1 Agonist

Lixisenatide

Also: Adlyxin

Short-acting prandial GLP-1, mostly clinically displaced now.

Evidence
established
Legal status
approved some regions
Half-life
Short (~hours)
Routes
subq
View on Limitless LifeAdd to compare
What it is

Short-acting prandial GLP-1, mostly clinically displaced now.

Mechanism

Short-acting prandial GLP-1, mostly clinically displaced now.

Outcomes it's matched to
Safety

Educational reference only. Long-term human safety varies; consult a peptide-literate clinician.

Legal context

FDA approved

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault